Targeting carboxypeptidase A/B activity with the phosphinic inhibitor C28 reduces the asthmatic response in a mouse model of house dust mite-induced asthma

Objective Metallo-carboxypeptidases are implicated in several pathological contexts but their role in asthma and their potential as therapeutic targets in asthmatic settings are only partly understood. This study sought to investigate whether inhibition of carboxypeptidase activity of A and B-type c...

Full description

Saved in:
Bibliographic Details
Published inInflammation research Vol. 74; no. 1; p. 80
Main Authors Allam, Venkata Sita Rama Raju, Montpeyó, David, Beau, Fabrice, Taha, Sowsan, Waern, Ida, Akula, Srinivas, Avilés, Francesc Xavier, Lorenzo, Julia, Devel, Laurent, Pejler, Gunnar, Wernersson, Sara
Format Journal Article
LanguageEnglish
Published Cham Springer International Publishing 01.12.2025
Springer Nature B.V
Springer Verlag
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Objective Metallo-carboxypeptidases are implicated in several pathological contexts but their role in asthma and their potential as therapeutic targets in asthmatic settings are only partly understood. This study sought to investigate whether inhibition of carboxypeptidase activity of A and B-type could mitigate asthma-like symptoms in a mouse model of allergic airway inflammation. Methods BALB/c mice were sensitized and challenged with repeated intranasal instillations of 10 µg house dust mite extract. Prior to each instillation, groups of mice received intraperitoneally from 0.2 to 1 mg/kg of compound 28, a phosphinic inhibitor of A/B-type carboxypeptidases. Manifestations of asthma-like features were assessed, including airway hyperresponsiveness, airway inflammation, lung histopathology and inflammatory markers. Results Treatment with compound 28 protected against airway hyperresponsiveness and profoundly reduced the house dust mite-induced inflammation both in airways and in lung tissue. Moreover, compound 28 could mitigate airway smooth muscle and goblet cell remodelling as well as inflammatory gene expression in the lungs. Conclusions Compound 28 could suppress multiple features of asthma in a physiologically relevant mouse model, reinforcing the potential of targeting A/B type carboxypeptidases for therapeutic purposes in allergic asthma.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMCID: PMC12103337
Responsible Editor: Bernhard Gibbs.
ISSN:1023-3830
1420-908X
1420-908X
DOI:10.1007/s00011-025-02046-z